EXEL
Exelixis Inc
Halal Rating :
Last Price
$36.20
Last updated:
Market Cap
-
7D Change
2.55%
1 Year Change
59.89%
Company Overview
Industries
Exchange
Next Earnings Date
Exelixis Inc is a biopharmaceutical company focused on developing and commercializing medicines for difficult-to-treat cancers. The company's flagship product is CABOMETYX® (cabozantinib), which is approved for the treatment of various types of cancer including advanced renal cell carcinoma and hepatocellular carcinoma.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 27, 2024 | $539.54m | $403.47m | - | - | 0.00% | 0.00% |
| June 28, 2024 | $637.18m | $361.3m | - | - | 0.00% | 0.00% |
| March 29, 2024 | $425.23m | $395.76m | - | - | 0.00% | 0.00% |
Company Impact
Help us evaluate Exelixis Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.